Cargando…

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

BACKGROUND: BRCAness is defined as shared tumour characteristics between sporadic and BRCA-mutated cancers. However, how to exactly measure BRCAness and its frequency in breast cancer is not known. Assays to establish BRCAness would be extremely valuable for the clinical management of these tumours....

Descripción completa

Detalles Bibliográficos
Autores principales:	Lips, E H, Mulder, L, Oonk, A, van der Kolk, L E, Hogervorst, F B L, Imholz, A L T, Wesseling, J, Rodenhuis, S, Nederlof, P M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Genetics and Genomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670471/ https://www.ncbi.nlm.nih.gov/pubmed/23558900 http://dx.doi.org/10.1038/bjc.2013.144

Ejemplares similares

Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness
por: Lips, Esther H, et al.
Publicado: (2011)

BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer
por: Lips, Esther H., et al.
Publicado: (2020)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2
por: Osorio, A, et al.
Publicado: (2011)

A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers
por: Kadouri, L, et al.
Publicado: (2004)

Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
por: Osorio, A, et al.
Publicado: (2009)

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years
por: Robertson, L, et al.
Publicado: (2012)

The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Sinilnikova, O M, et al.
Publicado: (2009)

Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study
por: Phelan, C M, et al.
Publicado: (2014)

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
por: Edwards, S M, et al.
Publicado: (2010)

Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype
por: Mitra, A, et al.
Publicado: (2008)

A multiplex PCR predictor for aCGH success of FFPE samples
por: van Beers, E H, et al.
Publicado: (2006)

Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response
por: Lips, Esther H., et al.
Publicado: (2015)

An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers
por: Osorio, A, et al.
Publicado: (2008)

Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers
por: Kadouri, L, et al.
Publicado: (2008)

Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers
por: Kote-Jarai, Z, et al.
Publicado: (2006)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Using next‐generation sequencing to redefine BRCAness in triple‐negative breast cancer
por: Lin, Po‐Han, et al.
Publicado: (2020)

BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families
por: Claes, K, et al.
Publicado: (2004)

Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer
por: Agalliu, I, et al.
Publicado: (2007)

Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study
por: Jakubowska, A, et al.
Publicado: (2012)

Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation
por: Metcalfe, K A, et al.
Publicado: (2009)

Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of ‘easy to apply’ probability models
por: Bodmer, D, et al.
Publicado: (2006)

Germline BRCA1 mutations increase prostate cancer risk
por: Leongamornlert, D, et al.
Publicado: (2012)

Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women
por: Sidon, L, et al.
Publicado: (2012)

BRCA1 and BRCA2 mutations in Scotland and Northern Ireland
Publicado: (2003)

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions
por: Moon, D H, et al.
Publicado: (2013)

DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas
por: Kamieniak, M M, et al.
Publicado: (2013)

Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach
por: Gille, J J P, et al.
Publicado: (2002)

Low-level constitutional mosaicism of a de novoBRCA1 gene mutation
por: Friedman, E, et al.
Publicado: (2015)

CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status
por: Gudmundsdottir, K, et al.
Publicado: (2003)

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy
por: Vollebergh, Marieke A, et al.
Publicado: (2014)

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial
por: Vliek, Sonja, et al.
Publicado: (2023)

Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use
por: Abbotts, Rachel, et al.
Publicado: (2022)

The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study
por: Iqbal, Javaid, et al.
Publicado: (2016)

Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment
por: Campbell, Aideen M, et al.
Publicado: (2018)

Quantifying concordant genetic effects of de novo mutations on multiple disorders
por: Guo, Hanmin, et al.
Publicado: (2022)

Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia
por: Scardocci, A, et al.
Publicado: (2006)

Abnormality of the DNA double-strand-break checkpoint/repair genes, ATM, BRCA1 and TP53, in breast cancer is related to tumour grade
por: Ding, S L, et al.
Publicado: (2004)

BRCAness in prostate cancer
por: Bednarz-Knoll, Natalia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_a659p7oin0fmqf75k5ul2bupks